Advertisement

The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Keedwell P.A.
        • Andrew C.
        • Williams S.C.
        • et al.
        The neural correlates of anhedonia in major depressive disorder.
        Biol Psychiatry. 2005; 58: 843-853
        • Drevets W.C.
        Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders.
        Curr Opin Neurobiol. 2001; 11: 240-249
        • Miller E.K.
        • Cohen J.D.
        An integrative theory of prefrontal cortex function.
        Annu Rev Neurosci. 2001; 24: 167-202
        • Treede R.D.
        • Kenshalo D.R.
        • Gracely R.H.
        • et al.
        The cortical representation of pain.
        Pain. 1999; 79: 105-111
        • Vogt B.A.
        • Finch D.M.
        • Olson C.R.
        Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions.
        Cereb Cortex. 1992; 2: 435-443
        • Gysling K.
        • Forray M.I.
        • Haeger P.
        • et al.
        Corticotropin-releasing hormone and urocortin: redundant or distinctive functions?.
        Brain Res Brain Res Rev. 2004; 47: 116-125
        • Barrera G.
        • Echevarria D.J.
        • Poulin J.F.
        • et al.
        One for all or one for one: does co-transmission unify the concept of a brain galanin “system” or clarify any consistent role in anxiety?.
        Neuropeptides. 2005; 39: 289-292
        • Honkaniemi J.
        • Pelto-Huikko M.
        • Rechardt L.
        • et al.
        Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus.
        Neuroendocrinology. 1992; 55: 451-459
        • Palkovits M.
        Stress-induced expression of co-localized neuropeptides in hypothalamic and amygdaloid neurons.
        Eur J Pharmacol. 2000; 405: 161-166
        • Watts A.G.
        The impact of physiological stimuli on the expression of corticotropin-releasing hormone (CRH) and other neuropeptide genes.
        Front Neuroendocrinol. 1996; 17: 281-326
        • Cole R.L.
        • Sawchenko P.E.
        Neurotransmitter regulation of cellular activation and neuropeptide gene expression in the paraventricular nucleus of the hypothalamus.
        J Neurosci. 2002; 22: 959-969
        • Holmes A.
        • Heilig M.
        • Rupniak N.M.
        • et al.
        Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
        Trends Pharmacol Sci. 2003; 24: 580-588
      1. Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. 3rd edition. Washington, DC: The American Psychiatric Publishing; 2004. p. 716–65, 847–68, 913–35.

        • Lang R.
        • Gundlach A.L.
        • Kofler B.
        The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease.
        Pharmacol Ther. 2007; 115: 177-207
        • Liu H.X.
        • Hokfelt T.
        The participation of galanin in pain processing at the spinal level.
        Trends Pharmacol Sci. 2002; 23: 468-474
        • Bedecs K.
        • Berthold M.
        • Bartfai T.
        Galanin 10 years with a neuroendocrine peptide.
        Int J Biochem Cell Biol. 1995; 27: 337-349
        • Gimpl G.
        • Fahrenholz F.
        The oxytocin receptor system: structure, function, and regulation.
        Physiol Rev. 2001; 81: 629-683
        • Meyer-Lindenberg A.
        Impact of prosocial neuropeptides on human brain function.
        Prog Brain Res. 2008; 170: 463-470
        • Egashira N.
        • Tanoue A.
        • Matsuda T.
        • et al.
        Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice.
        Behav Brain Res. 2007; 178: 123-127
        • Kendler K.S.
        • Gardner C.O.
        • Lichtenstein P.
        A developmental twin study of symptoms of anxiety and depression: evidence for genetic innovation and attenuation.
        Psychol Med. 2008; 38: 1567-1575
        • Hallett V.
        • Ronald A.
        • Rijsdijk F.
        • et al.
        Phenotypic and genetic differentiation of anxiety-related behaviors in middle childhood.
        Depress Anxiety. 2009; 26: 316-324
        • Lee Y.S.
        • Hwang J.
        • Kim S.J.
        • et al.
        Decreased blood flow of temporal regions of the brain in subjects with panic disorder.
        J Psychiatr Res. 2006; 40: 528-534
        • Engel K.
        • Bandelow B.
        • Gruber O.
        • et al.
        Neuroimaging in anxiety disorders.
        J Neural Transm. 2009; 116: 703-716
        • Pfleiderer B.
        • Zinkirciran S.
        • Arolt V.
        • et al.
        fMRI amygdala activation during a spontaneous panic attack in a patient with panic disorder.
        World J Biol Psychiatry. 2007; 8: 269-272
        • Maddock R.J.
        • Buonocore M.H.
        • Kile S.J.
        • et al.
        Brain regions showing increased activation by threat-related words in panic disorder.
        Neuroreport. 2003; 14: 325-328
        • van den Heuvel O.A.
        • Veltman D.J.
        • Groenewegen H.J.
        • et al.
        Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis.
        Arch Gen Psychiatry. 2005; 62: 922-933
        • Bystritsky A.
        • Pontillo D.
        • Powers M.
        • et al.
        Functional MRI changes during panic anticipation and imagery exposure.
        Neuroreport. 2001; 12: 3953-3957
        • Pillay S.S.
        • Gruber S.A.
        • Rogowska J.
        • et al.
        fMRI of fearful facial affect recognition in panic disorder: the cingulate gyrus-amygdala connection.
        J Affect Disord. 2006; 94: 173-181
        • Malizia A.L.
        • Cunningham V.J.
        • Bell C.J.
        • et al.
        Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study.
        Arch Gen Psychiatry. 1998; 55: 715-720
        • Bremner J.D.
        • Innis R.B.
        • Southwick S.M.
        • et al.
        Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder.
        Am J Psychiatry. 2000; 157: 1120-1126
        • Bremner J.D.
        • Innis R.B.
        • White T.
        • et al.
        SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder.
        Biol Psychiatry. 2000; 47: 96-106
        • Kaschka W.
        • Feistel H.
        • Ebert D.
        Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT.
        J Psychiatr Res. 1995; 29: 427-434
        • Goddard A.W.
        • Mason G.F.
        • Appel M.
        • et al.
        Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder.
        Am J Psychiatry. 2004; 161: 2186-2193
        • Ham B.J.
        • Sung Y.
        • Kim N.
        • et al.
        Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study.
        Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 403-411
        • Kent J.M.
        • Mathew S.J.
        • Gorman J.M.
        Molecular targets in the treatment of anxiety.
        Biol Psychiatry. 2002; 52: 1008-1030
        • Helton D.R.
        • Tizzano J.P.
        • Monn J.A.
        • et al.
        Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
        J Pharmacol Exp Ther. 1998; 284: 651-660
        • Cortese B.M.
        • Phan K.L.
        The role of glutamate in anxiety and related disorders.
        CNS Spectr. 2005; 10: 820-830
        • Pull C.B.
        • Damsa C.
        Pharmacotherapy of panic disorder.
        Neuropsychiatr Dis Treat. 2008; 4: 779-795
        • Vaswani M.
        • Linda F.K.
        • Ramesh S.
        Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
        Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 85-102
        • Neumeister A.
        • Young T.
        • Stastny J.
        Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter.
        Psychopharmacology (Berl). 2004; 174: 512-524
        • Unschuld P.G.
        • Ising M.
        • Erhardt A.
        • et al.
        Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder.
        J Affect Disord. 2008; 105: 177-184
        • Abelson J.L.
        • Khan S.
        • Liberzon I.
        • et al.
        HPA axis activity in patients with panic disorder: review and synthesis of four studies.
        Depress Anxiety. 2007; 24: 66-76
        • Hettema J.M.
        • Neale M.C.
        • Kendler K.S.
        A review and meta-analysis of the genetic epidemiology of anxiety disorders.
        Am J Psychiatry. 2001; 158: 1568-1578
        • Hettema J.M.
        • Prescott C.A.
        • Myers J.M.
        • et al.
        The structure of genetic and environmental risk factors for anxiety disorders in men and women.
        Arch Gen Psychiatry. 2005; 62: 182-189
        • Smoller J.W.
        • Gardner-Schuster E.
        • Covino J.
        The genetic basis of panic and phobic anxiety disorders.
        Am J Med Genet C Semin Med Genet. 2008; 148: 118-126
        • Finn C.T.
        • Smoller J.W.
        The genetics of panic disorder.
        Curr Psychiatry Rep. 2001; 3: 131-137
        • Fyer A.J.
        • Hamilton S.P.
        • Durner M.
        • et al.
        A third-pass genome scan in panic disorder: evidence for multiple susceptibility loci.
        Biol Psychiatry. 2006; 60: 388-401
        • Lesch K.P.
        • Bengel D.
        • Heils A.
        • et al.
        Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.
        Science. 1996; 274: 1527-1531
        • Strug L.J.
        • Suresh R.
        • Fyer A.J.
        • et al.
        Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR).
        Mol Psychiatry. 2010; 15: 166-176
        • Keck M.E.
        • Kern N.
        • Erhardt A.
        • et al.
        Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder.
        Am J Med Genet B Neuropsychiatr Genet. 2008; 147B: 1196-1204
        • Hodges L.M.
        • Weissman M.M.
        • Haghighi F.
        • et al.
        Association and linkage analysis of candidate genes GRP, GRPR, CRHR1, and TACR1 in panic disorder.
        Am J Med Genet B Neuropsychiatr Genet. 2009; 150B: 65-73
        • Bryant R.A.
        • Felmingham K.
        • Kemp A.
        • et al.
        Amygdala and ventral anterior cingulate activation predicts treatment response to cognitive behaviour therapy for post-traumatic stress disorder.
        Psychol Med. 2008; 38: 555-561
        • Dickie E.W.
        • Brunet A.
        • Akerib V.
        • et al.
        An fMRI investigation of memory encoding in PTSD: influence of symptom severity.
        Neuropsychologia. 2008; 46: 1522-1531
        • Bryant R.A.
        • Felmingham K.
        • Whitford T.J.
        • et al.
        Rostral anterior cingulate volume predicts treatment response to cognitive-behavioural therapy for posttraumatic stress disorder.
        J Psychiatry Neurosci. 2008; 33: 142-146
        • Morey R.A.
        • Petty C.M.
        • Cooper D.A.
        • et al.
        Neural systems for executive and emotional processing are modulated by symptoms of posttraumatic stress disorder in Iraq war veterans.
        Psychiatry Res. 2008; 162: 59-72
        • Falconer E.
        • Bryant R.
        • Felmingham K.L.
        • et al.
        The neural networks of inhibitory control in posttraumatic stress disorder.
        J Psychiatry Neurosci. 2008; 33: 413-422
        • Strawn J.R.
        • Geracioti Jr., T.D.
        Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.
        Depress Anxiety. 2008; 25: 260-271
        • Pervanidou P.
        Biology of post-traumatic stress disorder in childhood and adolescence.
        J Neuroendocrinol. 2008; 20: 632-638
        • Hurlemann R.
        Noradrenergic-glucocorticoid mechanisms in emotion-induced amnesia: from adaptation to disease.
        Psychopharmacology (Berl). 2008; 197: 13-23
        • Marshall R.D.
        • Schneier F.R.
        • Fallon B.A.
        • et al.
        An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder.
        J Clin Psychopharmacol. 1998; 18: 10-18
      2. Committee on Treatment of Posttraumatic Stress Disorder, Institute of Medicine. Treatment of posttraumatic stress disorder: an assessment of the evidence.
        National Academies Press, Washington, DC2008
        • Yehuda R.
        • Brand S.
        • Yang R.K.
        Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping.
        Biol Psychiatry. 2006; 59: 660-663
        • Yehuda R.
        Biology of posttraumatic stress disorder.
        J Clin Psychiatry. 2001; 62: 41-46
        • Yehuda R.
        • Giller E.L.
        • Southwick S.M.
        • et al.
        Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder.
        Biol Psychiatry. 1991; 30: 1031-1048
        • de Kloet C.S.
        • Vermetten E.
        • Geuze E.
        • et al.
        Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review.
        J Psychiatr Res. 2006; 40: 550-567
        • Risbrough V.B.
        • Stein M.B.
        Role of corticotropin releasing factor in anxiety disorders: a translational research perspective.
        Horm Behav. 2006; 50: 550-561
        • Fossey M.D.
        • Lydiard R.B.
        • Ballenger J.C.
        • et al.
        Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects.
        Biol Psychiatry. 1996; 39: 703-707
        • Nutt D.J.
        Neurobiological mechanisms in generalized anxiety disorder.
        J Clin Psychiatry. 2001; 62 ([discussion: 28]): 22-27
        • Yehuda R.
        • Southwick S.M.
        • Nussbaum G.
        • et al.
        Low urinary cortisol excretion in patients with posttraumatic stress disorder.
        J Nerv Ment Dis. 1990; 178: 366-369
        • Olff M.
        • Guzelcan Y.
        • de Vries G.J.
        • et al.
        HPA- and HPT-axis alterations in chronic posttraumatic stress disorder.
        Psychoneuroendocrinology. 2006; 31: 1220-1230
        • Rasmusson A.M.
        • Lipschitz D.S.
        • Wang S.
        • et al.
        Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder.
        Biol Psychiatry. 2001; 50: 965-977
        • Lipschitz D.S.
        • Rasmusson A.M.
        • Yehuda R.
        • et al.
        Salivary cortisol responses to dexamethasone in adolescents with posttraumatic stress disorder.
        J Am Acad Child Adolesc Psychiatry. 2003; 42: 1310-1317
        • Baker D.G.
        • Ekhator N.N.
        • Kasckow J.W.
        • et al.
        Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder.
        Neuroimmunomodulation. 2001; 9: 209-217
        • Bremner J.D.
        • Licinio J.
        • Darnell A.
        • et al.
        Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.
        Am J Psychiatry. 1997; 154: 624-629
        • Smith M.A.
        • Davidson J.
        • Ritchie J.C.
        • et al.
        The corticotropin-releasing hormone test in patients with posttraumatic stress disorder.
        Biol Psychiatry. 1989; 26: 349-355
        • Yehuda R.
        • Halligan S.L.
        • Grossman R.
        • et al.
        The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder.
        Biol Psychiatry. 2002; 52: 393-403
        • Kudler H.
        • Davidson J.
        • Meador K.
        • et al.
        The DST and posttraumatic stress disorder.
        Am J Psychiatry. 1987; 144: 1068-1071
        • Raison C.L.
        • Miller A.H.
        When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders.
        Am J Psychiatry. 2003; 160: 1554-1565
        • Segman R.H.
        • Shalev A.Y.
        Genetics of posttraumatic stress disorder.
        CNS Spectr. 2003; 8: 693-698
        • Yehuda R.
        • Halligan S.L.
        • Bierer L.M.
        Relationship of parental trauma exposure and PTSD to PTSD, depressive and anxiety disorders in offspring.
        J Psychiatr Res. 2001; 35: 261-270
        • Yehuda R.
        • Halligan S.L.
        • Grossman R.
        Childhood trauma and risk for PTSD: relationship to intergenerational effects of trauma, parental PTSD, and cortisol excretion.
        Dev Psychopathol. 2001; 13: 733-753
        • Koenen K.C.
        • Lyons M.J.
        • Goldberg J.
        • et al.
        A high risk twin study of combat-related PTSD comorbidity.
        Twin Res. 2003; 6: 218-226
        • Stein M.B.
        • Jang K.L.
        • Taylor S.
        • et al.
        Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study.
        Am J Psychiatry. 2002; 159: 1675-1681
        • Heils A.
        • Teufel A.
        • Petri S.
        • et al.
        Allelic variation of human serotonin transporter gene expression.
        J Neurochem. 1996; 66: 2621-2624
        • Caspi A.
        • Sugden K.
        • Moffitt T.E.
        • et al.
        Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.
        Science. 2003; 301: 386-389
        • Eley T.C.
        • Sugden K.
        • Corsico A.
        • et al.
        Gene-environment interaction analysis of serotonin system markers with adolescent depression.
        Mol Psychiatry. 2004; 9: 908-915
        • Grabe H.J.
        • Lange M.
        • Wolff B.
        • et al.
        Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden.
        Mol Psychiatry. 2005; 10: 220-224
        • Kaufman J.
        • Yang B.Z.
        • Douglas-Palumberi H.
        • et al.
        Social supports and serotonin transporter gene moderate depression in maltreated children.
        Proc Natl Acad Sci U S A. 2004; 101: 17316-17321
        • Kendler K.S.
        • Kuhn J.W.
        • Vittum J.
        • et al.
        The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication.
        Arch Gen Psychiatry. 2005; 62: 529-535
        • Gillespie N.A.
        • Whitfield J.B.
        • Williams B.
        • et al.
        The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression.
        Psychol Med. 2005; 35: 101-111
        • Kaufman J.
        • Yang B.Z.
        • Douglas-Palumberi H.
        • et al.
        Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children.
        Biol Psychiatry. 2006; 59: 673-680
        • Kilpatrick D.G.
        • Koenen K.C.
        • Ruggiero K.J.
        • et al.
        The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults.
        Am J Psychiatry. 2007; 164: 1693-1699
        • Ladd C.O.
        • Huot R.L.
        • Thrivikraman K.V.
        • et al.
        Long-term behavioral and neuroendocrine adaptations to adverse early experience.
        Prog Brain Res. 2000; 122: 81-103
        • Plotsky P.M.
        • Thrivikraman K.V.
        • Nemeroff C.B.
        • et al.
        Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring.
        Neuropsychopharmacology. 2005; 30: 2192-2204
        • Bradley R.G.
        • Binder E.B.
        • Epstein M.P.
        • et al.
        Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene.
        Arch Gen Psychiatry. 2008; 65: 190-200
        • Binder E.B.
        • Bradley R.G.
        • Liu W.
        • et al.
        Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults.
        JAMA. 2008; 299: 1291-1305
        • Davies T.H.
        • Ning Y.M.
        • Sanchez E.R.
        A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins.
        J Biol Chem. 2002; 277: 4597-4600
        • Denny W.B.
        • Valentine D.L.
        • Reynolds P.D.
        • et al.
        Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding.
        Endocrinology. 2000; 141: 4107-4113
        • Wochnik G.M.
        • Ruegg J.
        • Abel G.A.
        • et al.
        FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells.
        J Biol Chem. 2005; 280: 4609-4616
        • Binder E.B.
        • Salyakina D.
        • Lichtner P.
        • et al.
        Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.
        Nat Genet. 2004; 36: 1319-1325
        • Newport D.J.
        • Heim C.
        • Bonsall R.
        • et al.
        Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse.
        Biol Psychiatry. 2004; 55: 10-20
        • Yehuda R.
        • Golier J.A.
        • Halligan S.L.
        • et al.
        The ACTH response to dexamethasone in PTSD.
        Am J Psychiatry. 2004; 161: 1397-1403
        • Segman R.H.
        • Shefi N.
        • Goltser-Dubner T.
        • et al.
        Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors.
        Mol Psychiatry. 2005; 10 (425): 500-513
        • Koenen K.C.
        • Saxe G.
        • Purcell S.
        • et al.
        Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children.
        Mol Psychiatry. 2005; 10: 1058-1059
        • Ozer E.J.
        • Best S.R.
        • Lipsey T.L.
        • et al.
        Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis.
        Psychol Bull. 2003; 129: 52-73
        • Kilts C.D.
        • Kelsey J.E.
        • Knight B.
        • et al.
        The neural correlates of social anxiety disorder and response to pharmacotherapy.
        Neuropsychopharmacology. 2006; 31: 2243-2253
        • Stein M.B.
        • Stein D.J.
        Social anxiety disorder.
        Lancet. 2008; 371: 1115-1125
        • Hood S.
        • Potokar J.
        • Davies S.
        • et al.
        Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants.
        J Psychopharmacol. 2010; 24: 709-716
        • Condren R.M.
        • O'Neill A.
        • Ryan M.C.
        • et al.
        HPA axis response to a psychological stressor in generalised social phobia.
        Psychoneuroendocrinology. 2002; 27: 693-703
        • Roelofs K.
        • van Peer J.
        • Berretty E.
        • et al.
        Hypothalamus-pituitary-adrenal axis hyperresponsiveness is associated with increased social avoidance behavior in social phobia.
        Biol Psychiatry. 2009; 65: 336-343
        • van Veen J.F.
        • van Vliet I.M.
        • Derijk R.H.
        • et al.
        Elevated alpha-amylase but not cortisol in generalized social anxiety disorder.
        Psychoneuroendocrinology. 2008; 33: 1313-1321
        • Martel F.L.
        • Hayward C.
        • Lyons D.M.
        • et al.
        Salivary cortisol levels in socially phobic adolescent girls.
        Depress Anxiety. 1999; 10: 25-27
        • De Bellis M.D.
        • Keshavan M.S.
        • Shifflett H.
        • et al.
        Superior temporal gyrus volumes in pediatric generalized anxiety disorder.
        Biol Psychiatry. 2002; 51: 553-562
        • Monk C.S.
        • Nelson E.E.
        • McClure E.B.
        • et al.
        Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder.
        Am J Psychiatry. 2006; 163: 1091-1097
        • Mathew S.J.
        • Mao X.
        • Coplan J.D.
        • et al.
        Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study.
        Am J Psychiatry. 2004; 161: 1119-1121
        • Herry C.
        • Ciocchi S.
        • Senn V.
        • et al.
        Switching on and off fear by distinct neuronal circuits.
        Nature. 2008; 454: 600-606
        • Izumi T.
        • Inoue T.
        • Kato A.
        • et al.
        Changes in amygdala neural activity that occur with the extinction of context-dependent conditioned fear stress.
        Pharmacol Biochem Behav. 2008; 90: 297-304
        • Davis M.
        • Walker D.L.
        • Myers K.M.
        Role of the amygdala in fear extinction measured with potentiated startle.
        Ann N Y Acad Sci. 2003; 985: 218-232
        • Anand A.
        • Shekhar A.
        Brain imaging studies in mood and anxiety disorders: special emphasis on the amygdala.
        Ann N Y Acad Sci. 2003; 985: 370-388
        • Rauch S.L.
        • Shin L.M.
        • Wright C.I.
        Neuroimaging studies of amygdala function in anxiety disorders.
        Ann N Y Acad Sci. 2003; 985: 389-410
        • Monk C.S.
        • Telzer E.H.
        • Mogg K.
        • et al.
        Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder.
        Arch Gen Psychiatry. 2008; 65: 568-576
        • McClure E.B.
        • Adler A.
        • Monk C.S.
        • et al.
        fMRI predictors of treatment outcome in pediatric anxiety disorders.
        Psychopharmacology (Berl). 2007; 191: 97-105
        • Whalen P.J.
        • Johnstone T.
        • Somerville L.H.
        • et al.
        A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder.
        Biol Psychiatry. 2008; 63: 858-863
        • Nemeroff C.B.
        The role of GABA in the pathophysiology and treatment of anxiety disorders.
        Psychopharmacol Bull. 2003; 37: 133-146
        • Mathew S.J.
        • Amiel J.M.
        • Coplan J.D.
        • et al.
        Open-label trial of riluzole in generalized anxiety disorder.
        Am J Psychiatry. 2005; 162: 2379-2381
        • Pittenger C.
        • Coric V.
        • Banasr M.
        • et al.
        Riluzole in the treatment of mood and anxiety disorders.
        CNS Drugs. 2008; 22: 761-786
        • Maron E.
        • Kuikka J.T.
        • Ulst K.
        • et al.
        SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder.
        Eur Arch Psychiatry Clin Neurosci. 2004; 254: 392-396
        • Malison R.T.
        • Price L.H.
        • Berman R.
        • et al.
        Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography.
        Biol Psychiatry. 1998; 44: 1090-1098
        • Koszycki D.
        • Copen J.
        • Bradwejn J.
        Sensitivity to cholecystokinin-tetrapeptide in major depression.
        J Affect Disord. 2004; 80: 285-290
        • Brawman-Mintzer O.
        • Lydiard R.B.
        • Bradwejn J.
        • et al.
        Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder.
        Am J Psychiatry. 1997; 154: 700-702
        • Pande A.C.
        • Greiner M.
        • Adams J.B.
        • et al.
        Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
        Biol Psychiatry. 1999; 46: 860-862
        • Heilig M.
        The NPY system in stress, anxiety and depression.
        Neuropeptides. 2004; 38: 213-224
        • Sajdyk T.J.
        • Shekhar A.
        • Gehlert D.R.
        Interactions between NPY and CRF in the amygdala to regulate emotionality.
        Neuropeptides. 2004; 38: 225-234
        • Lelas S.
        • Wong H.
        • Li Y.W.
        • et al.
        Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
        J Pharmacol Exp Ther. 2004; 309: 293-302
        • Millan M.J.
        • Brocco M.
        • Gobert A.
        • et al.
        Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent.
        Neuropsychopharmacology. 2001; 25: 585-600
        • Chaki S.
        • Nakazato A.
        • Kennis L.
        • et al.
        Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
        Eur J Pharmacol. 2004; 485: 145-158
        • Holsboer F.
        • Ising M.
        Central CRH system in depression and anxiety—evidence from clinical studies with CRH1 receptor antagonists.
        Eur J Pharmacol. 2008; 583: 350-357
        • Ninan P.T.
        Recent perspectives on the diagnosis and treatment of generalized anxiety disorder.
        Am J Manag Care. 2001; 7: S367-S376
        • Hettema J.M.
        • Prescott C.A.
        • Kendler K.S.
        A population-based twin study of generalized anxiety disorder in men and women.
        J Nerv Ment Dis. 2001; 189: 413-420
        • Tadic A.
        • Rujescu D.
        • Szegedi A.
        • et al.
        Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression.
        Am J Med Genet B Neuropsychiatr Genet. 2003; 117B: 1-6
        • You J.S.
        • Hu S.Y.
        • Chen B.
        • et al.
        Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder.
        Psychiatr Genet. 2005; 15: 7-11
        • Koenen K.C.
        • Amstadter A.B.
        • Ruggiero K.J.
        • et al.
        RGS2 and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults.
        Depress Anxiety. 2009; 26: 309-315